Immunizations is one of the public healthcare program for vaccination that prevents thousands of deaths, millions of cases of disease, and saves billions of dollars per decade. Immunizations are a safe, and effective way to protect children from disease including cancers, disability, and death. It is important during a pandemic or other public health emergency to maintain routine immunizations in order to prevent further outbreaks. There are various types of vaccines based on age group that include adult vaccines and pediatric vaccines. The pediatric vaccine is the first dose that is taken at birth. The next dose is taken when the child is 6 weeks old, the third dose at 10 weeks old, and the last dose at 14 weeks old. This vaccine protects against the poliovirus that is a highly infectious disease that invades the nervous system, and can lead to total paralysis.

Market Dynamics

Increasing approval of vaccines by regulatory authorities is expected to drive the market growth over the forecast period. For instance, on June 18, 2022, the Centers for Disease Control and Prevention (CDC) has approved COVID-19 vaccination for young children of age least 6 months old that means 20 million children, in the U.S., that are under 5 years are newly eligible for vaccination. For children under 5, there are two vaccines available. The three-dose Pfizer COVID-19 vaccine is provided to children 6 months to 4 years of age at a 3 microgram dosage. The two-dose Moderna COVID-19 vaccine is recommended for children of age 6 months to 5 years at a dose of 25 micrograms.

Key market players are focusing on increasing research and development activities for producing vaccines that employs various technologies to combat infections such as COVID-19 and others. For instance, in June 2022, Pfizer Inc., a multinational pharmaceutical and biotechnology, and BioNTech SE, a biotechnology company, announced positive data evaluating the safety, immunogenicity, and tolerability, of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent. A combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targets the spike protein of the Omicron BA.1 variant of concern. Data from the Phase 2/3 trial showed that a booster dose of both Omicron-adapted vaccine candidates has substantially higher immune response against Omicron BA.1, as compared to the companies’ current COVID-19 vaccine. The robust immune response was seen in two investigational dose levels, 30 µg and 60 µg. The Pfizer-BioNTech COVID-19 Vaccine that is based on BioNTech’s proprietary mRNA technology was developed by both BioNTech and Pfizer Inc.

Key features of the study:

• This report provides in-depth analysis of the global pediatric vaccines market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Pediatric Vaccines Market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech, and Indian Immunologicals Ltd.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global pediatric vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pediatric vaccines market

Detailed Segmentation:

• Global Pediatric Vaccines Market, By Vaccine Type:
  • Pneumococcal Vaccine
  • DTP Vaccine
  • Rotavirus Vaccine
  • MMR Vaccine
  • Polio Vaccine
  • Influenza Vaccine
  • Hepatitis B Vaccine
  • Meningococcal Vaccine
  • Hib Vaccine
  • Varicella Vaccine
• Global Pediatric Vaccines Market, By Technology :
  • Live or Attenuated Vaccine
  • Inactivated or Killed Vaccine
  • Toxoid Vaccine
  • Conjugate Vaccine
  • Subunit Vaccine
  • Recombinant Vaccine
• Global Pediatric Vaccines Market By Type:
  • Monovalent Vaccine
  • Multivalent Vaccine
• Global Pediatric Vaccines Market By Distribution Channel:
  • Government
  • Private
• Global Pediatric Vaccines Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Type:
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • GlaxoSmithKline Plc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Panacea Biotec
  • Zydus Cadila
  • Emergent BioSolutions Inc.
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech
  • Indian Immunologicals Ltd.

“*” marked represents similar segmentation in other categories in the respective section.